Skip to main content

Olink Acquires IP from In Situ RCP

NEW YORK (GenomeWeb News) – Olink Bioscience said today that it has acquired a family of patents from the Danish firm In Situ RCP that it plans to use in its nucleic acid amplification and protein analysis applications.

The Uppsala, Sweden-based company said the three patents are related to target primed rolling circle amplification and amplifying circular molecules.

Olink's product line is based on its proximity ligation assay technology, which uses dual recognition of analytes and a DNA amplification reporter system.

"The acquisition of these patents is an important step in the process to further strengthen our already strong position within the field of DNA-based immunoassays, as well as to allow us to expand into novel areas of nucleic acid based analysis based on rolling circle amplification," Mats Gullberg, CTO of Olink, said in a statement.

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.